Unmet needs in the management of chronic hepatitis B still remain
What is the latest epidemiological data for HBV?
How are people affected by HBV infection?
What is the impact of suboptimal treatment of HBV infection?
What should be the treatment goal for people living with CHB?
Why is HBsAg seroclearance* important in CHB?
What could be the impact of functional cure for people living with CHB?

Why is HBsAg seroclearance* important in CHB?

HBsAg seroclearance is associated with improved survival and reduction in complications associated with CHB¹⁷

Getting ahead of liver disease together

Footnotes & Abbrev

Close

*Based on assays with lower limit of detection ~0.05 IU/mL.
†Based on current knowledge, the best surrogate of HBV functional cure is HBsAg seroclearance confirmed on 2 occasions at least 6 months apart without requirement for anti-HBs seroconversion plus undetectable HBV DNA.¹⁹
‡Cause-specific estimates will have quite substantial uncertainty ranges depending on the available data sources.
§Open-label extension study.

CHB, chronic hepatitis B; DNA, deoxyribonucleic acid; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NA, nucleos(t)ide analogue; peg-IFN, pegylated interferon; QOL, quality of life.
Home
References
Close
1. World Health Organization. Hepatitis B Fact sheet. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Updated on June 24, 2022. Accessed April 2023.
2. GBD 2019 Hepatitis B Collaborators. Lancet Gastroenterol Hepatol 2022;7:796–829.
3. Polaris Observatory Collaborators. Lancet Gastroenterol Hepatol 2018;3:383–403.
4. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, Geneva, 2021. https://www.who.int/publications/i/item/9789240027077. Updated on 15 July 2021. Accessed April 2023.
5. Tu T, et al. Viruses 2020;12:515.
6. World Health Organization. Global Health Estimates 2019: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. Geneva, 2020. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death. Accessed April 2023.
7. Vittal A, Ghany MG. Clin Liver Dis 2019;23:417–32.
8. Llovet JM, et al. Nat Rev Dis Primers 2021;7:6.
9. Marcellin P, et al. Lancet 2013;381:468–75.
10. Tan DJH, et al. JAMA Netwk Open 2022;5:e2219407.
11. Terrault NA, et al. Hepatology 2018;67:1560–99.
12. Moini M, Fung S. Viruses 2022;14:657.
13. Jeng WJ, et al. Hepatology 2018;68:425–34.
14. Tang LSY, et al. JAMA 2018;319:1802–13.
15. Terrault NA, et al. Hepatology 2016;63:261–83.
16. Choi HSJ, et al. Hepatol Commun 2022;6:935–49.
17. Anderson RT, et al. Clin Gastroenterol Hepatol 2021;19:463–72.
18. Buti M, et al. Dig Dis Sci 2015;60:1457–64.
19. Lampertico P. J Hepatol 2017;67:370–98.
20. Cornberg M, et al. J Hepatol 2020;72:539–57.

Getting ahead of liver disease together

This educational content has been developed and sponsored by
GSK Medical Affairs and it is intended for Healthcare Professionals only.
© 2001-2023 GSK plc. All rights reserved.
GSK is a registered trademark of GSK plc.

PSE-US-2039 August 2023